Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Mar;62(3):276-7.
doi: 10.1136/thx.2004.035519.

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody

Cornelis K van der Ent  1 , Hans Hoekstra, Ger T Rijkers
Affiliations
Case Reports

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody

Cornelis K van der Ent et al. Thorax. 2007 Mar.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. Stevens D A, Moss R B, Kurup V P, and participants in the Cystic Fibrosis Foundation Consensus Conference et al Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 200337(Suppl 3)S225–S264. - PubMed
    1. Holgate S T, Chuchalin A G, Hebert J.et al Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 200434632–638. - PubMed
    1. El Dahr J M, Fink R, Selden R.et al Development of immune responses to Aspergillus at an early age in children with cystic fibrosis. Am J Respir Crit Care Med 19941501513–1518. - PubMed
    1. Leser C, Kaufmann H F, Virchow C., Sret al Specific serum immunopatterns in clinical phases of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 199290589–599. - PubMed
    1. Hochhaus G, Brookman L, Fox H.et al Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 200319491–498. - PubMed

Publication types

MeSH terms